EGFR Changes in Breast Cancer Cells and Tamoxifen Resistance
Author Information
Author(s): B. Long, B.M. McKibben, M. Lynch, H.W. van den Berg
Primary Institution: The Queen's University of Belfast
Hypothesis
The study investigates the relationship between epidermal growth factor receptor (EGFR) expression and tamoxifen resistance in breast cancer cell lines.
Conclusion
The study found that tamoxifen resistance in breast cancer cells is associated with increased EGFR expression, and reversing this resistance leads to a decrease in EGFR levels.
Supporting Evidence
- ZR-75-9al cells showed increased EGFR expression compared to the parent line.
- Reversal of tamoxifen resistance was linked to a decrease in EGFR levels.
- ZR-PR-LT cells had significantly lower EGFR expression.
- EGFR expression was measured using high-affinity binding assays.
Takeaway
Breast cancer cells that resist tamoxifen treatment have more EGFR, and when the resistance is reversed, they have less EGFR again.
Methodology
The study examined EGFR expression in ZR-75-1 breast cancer cells and its variants using receptor assays and proliferation tests.
Limitations
The study does not clarify whether the observed changes in receptor expression are due to selection from the parent line or phenotypic alteration.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website